ALHAMBRA
1. Target Overview & Investment Thesis
ALHAMBRA is a 97-bed suburban community hospital in LOS ANGELES, CA with $48.1M in net patient revenue and a 34.6% operating margin. The hospital serves a payer mix of 10.6% Medicare, 26.4% Medicaid, and 63.0% commercial.
Thesis: Turnaround. Our ML models identify $3.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 34.6% to 42.0% (+736bps).
| Net Revenue HCRIS | $48.1M |
| Current EBITDA COMPUTED | $16.6M |
| Operating Margin COMPUTED | 34.6% |
| Occupancy HCRIS | 90.9% |
| Revenue / Bed COMPUTED | $496K |
| Net-to-Gross HCRIS | 61.8% |
| Distress Probability ML | 48.1% |
2. Market Context & Competitive Position
CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 34.6% places it above the state median. Among 171 size-comparable peers (48-194 beds), the median margin is -3.9%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (48-194), prioritizing same-state peers. 171 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| ALHAMBRA (Target) | CA | 97 | $48.1M | 34.6% |
| CHILDRENS HOSP & RES CNTR OAKL | CA | 155 | $687.9M | -7.1% |
| CONTRA COSTA REGIONAL MEDICAL | CA | 124 | $595.0M | -29.2% |
| KFH - VALLEJO | CA | 184 | $531.7M | 0.3% |
| RANCHO LOS AMIGOS NATL.REHAB.C | CA | 83 | $512.6M | 41.9% |
| CMH OF SAN BUENAVENTURA | CA | 170 | $498.5M | -7.6% |
| USC NORRIS CANCER HOSPITAL | CA | 60 | $468.7M | 19.1% |
| KFH - SANTA ROSA | CA | 172 | $458.9M | 0.4% |
| KFH - FRESNO | CA | 169 | $456.9M | 13.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.0M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $962K | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $952K | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $585K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $31K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $16.6M |
| + RCM Uplift | +$3.5M |
| Pro Forma EBITDA | $20.2M |
| Current Margin | 34.6% |
| Pro Forma Margin | 42.0% |
| WC Released (1x) | $1.8M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $25.6M | $145.1M | 5.67x | 41.5% |
| Base (11x exit) | 10.0x | 11.0x | $25.6M | $167.9M | 6.56x | 45.7% |
| Bull Case | 9.0x | 11.0x | $23.0M | $187.9M | 8.16x | 52.2% |
| Bull (12x exit) | 9.0x | 12.0x | $23.0M | $211.8M | 9.20x | 55.9% |
| Bear Case | 11.0x | 10.0x | $28.2M | $119.1M | 4.23x | 33.4% |
| Bear (11x exit) | 11.0x | 11.0x | $28.2M | $140.2M | 4.98x | 37.9% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Elevated Medicaid exposure (26.4%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 171 hospitals with 48-194 beds
- Same-state prioritization (n=172)
- Comp margins: P25=-20.2% / P50=-3.9% / P75=4.0%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.